Kawasaki disease (KD) is a multisystem
vasculitis of unknown etiology, with coronary artery
aneurysms occurring in majority of untreated cases.
Tumor necrosis factor (TNF)-α is the pleiotropic inflammatory
cytokine elevated during the acute phase of KD, which induces damage to vascular endothelial cells to cause
systemic vasculitis. We here investigated the potential role of
perifosine, a novel Akt inhibitor, on TNFα expression in LPS-stimulated macrophages and in ex-vivo cultured peripheral blood mononuclear cells (PBMCs) of acute KD patients. Here, we found that
perifosine inhibited LPS-induced TNFα expression and production in mouse macrophages (RAW 264.7 cells and bone marrow-derived macrophages (BMDMs)). Meanwhile,
perifosine administration down-regulated TNFα production in PBMCs isolated from acute KD patients. For the mechanism study, we found that
perifosine significantly inhibited Akt and ERK/
mitogen-activated protein kinases (MAPK) signaling, while activating
AMP-activated protein kinase (AMPK) signaling in both patients' PBMCs and LPS-stimulated macrophages. Interestingly, although
perifosine is generally known as an Akt inhibitor, our data suggested that ERK inhibition and AMPK activation, but not Akt inactivation were possibly involved in
perifosine-mediated inhibition against TNFα production in monocytes. In conclusion, our data suggested that
perifosine significantly inhibited TNFα production via regulation multiple signaling pathways. The results of this study should have significant translational relevance in managing this devastating disease.